Charles Schwab’s OnKure Therapeutics OKUR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$173K Hold
63,640
– – ﹤0.01% 3383
2026
Q2
$290K Buy
+63,640
New +$273K ﹤0.01% 3335
2024
Q2
– Sell
-3,750
Closed -$62.3K – 3690
2024
Q1
$62.3K Hold
3,750
– – ﹤0.01% 3347
2023
Q4
$60K Hold
3,750
– – ﹤0.01% 3387
2023
Q3
$286K Buy
3,750
+795
+27% +$54.1K ﹤0.01% 3227
2023
Q2
$194K Buy
+2,955
New +$238K ﹤0.01% 3311
2022
Q2
– Sell
-1,883
Closed -$56K – 3663
2022
Q1
$56K Hold
1,883
– – ﹤0.01% 3513
2021
Q4
$161K Buy
1,883
+546
+41% +$40.1K ﹤0.01% 3389
2021
Q3
$100K Hold
1,337
– – ﹤0.01% 3382
2021
Q2
$125K Buy
+1,337
New +$149K ﹤0.01% 3285

Other funds holding OKUR

Charles Schwab's OKUR Position: Q3 2026 in Review

Charles Schwab held its OnKure Therapeutics (OKUR) position steady in Q3 2026 at 63,640 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #3383.

Charles Schwab first reported a position in OKUR in Q2 2021 and has held it in 10 quarters since. The position peaked at $290K in Q2 2026. 83 funds tracked by Wall St. Rank hold OKUR as of Q3 2026.

  • Charles Schwab held 63,640 shares of OnKure Therapeutics worth $173K as of Q3 2026.
  • Charles Schwab left its OnKure Therapeutics share count unchanged in Q3 2026.
  • OnKure Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q3 2026, its #3383 holding.
  • Charles Schwab first reported a position in OnKure Therapeutics in Q2 2021 and has held it in 10 quarters since.
  • Charles Schwab's OnKure Therapeutics position peaked at $290K in Q2 2026.
  • 83 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q3 2026.

Based on Charles Schwab's 13F filing for Q3 2026, filed 16 Nov 2026.